Cell line · CVCL_0504
Papers153
1 to 20 of 153
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 42999633 | Immunotargets Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrative genomics and experimental validation identify a mechanosensitive gene signature associated with colorectal cancer liver metastasis. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MZF1 Inhibits TGFβ-1/SMAD Signaling by Transcriptionally Activating SnoN to Augment Tumorigenic Potential in Colon Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Differential Sensitivity to xCT-inhibition by ME1 expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Novel tRNA Half mt-5'-tiRNA-Tyr Promotes Colorectal Cancer Proliferation via Inducing HARS2 Succinylation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR Screening Identifies SMARCAL1 and MRN as Modulators of WRN Dependency in MSI-H Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RBMX promotes colorectal liver metastasis by stabilizing MTHFD2 mRNA to regulate redox homeostasis. | Cell Mol Life Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. | Genome Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxic CAF studies unveil PTHrP‑vitamin D‑RAS axis as pivotal in the CAF. | Oncol Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IFITM1-targeted NIR-II fluorescence imaging enables visualisation of colorectal cancer and metastatic lymph nodes. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0504/papers